Quick Answer
AVENUE THERAPEUTICS, INC. reported Operating Income Loss of -$3.08 million for the year ending 2025.
- AVENUE THERAPEUTICS, INC. showed an increase of +72.7% in Operating Income Loss from 2024 to 2025.
- This data is from AVENUE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$840.0 thousand | Q2 2016: -$638.0 thousand | Q3 2016: -$383.0 thousand | Q1 2017: -$504.0 thousand | Q2 2017: -$1.74 million | Q3 2017: -$2.85 million | Q1 2018: -$10.43 million | Q2 2018: -$4.68 million | Q3 2018: -$2.61 million | Q1 2019: -$11.36 million | Q2 2019: -$7.11 million | Q3 2019: -$2.32 million | Q1 2020: -$1.27 million | Q2 2020: -$1.90 million | Q3 2020: -$1.04 million | Q1 2021: -$1.00 million | Q2 2021: -$951.0 thousand | Q3 2021: -$872.0 thousand | Q1 2022: -$2.86 million | Q2 2022: -$605.0 thousand | Q3 2022: -$663.0 thousand | Q1 2023: -$6.43 million | Q2 2023: -$3.92 million | Q3 2023: -$2.07 million | Q1 2024: -$3.71 million | Q2 2024: -$2.82 million | Q3 2024: -$3.16 million | Q1 2025: -$1.91 million | Q2 2025: $297.0 thousand | Q3 2025: -$724.0 thousand.
- Over the full 11 years of available data (2015 to 2025), AVENUE THERAPEUTICS, INC.'s Operating Income Loss has grown by 36.3%.
- Historical annual values: Fiscal year 2025: -$3.08 million | Fiscal year 2024: -$11.28 million | Fiscal year 2023: -$14.54 million | Fiscal year 2022: -$8.04 million | Fiscal year 2021: -$3.74 million | Fiscal year 2020: -$5.21 million | Fiscal year 2019: -$26.27 million | Fiscal year 2018: -$21.82 million | Fiscal year 2017: -$11.42 million | Fiscal year 2016: -$2.38 million | Fiscal year 2015: -$4.84 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: